Clinical

Any detectable high-sensitivity cardiac troponin T (hs-cTn) level is associated with adverse outcomes


 

Clinical question: What is the association between high-sensitivity cardiac troponin T (hs-cTn) levels and outcomes in patients with chest pain?

Background: There are few data on the link between hs-cTn levels and outcomes in patients with chest pain but no myocardial infarction or any other condition that can cause acute increases in troponin levels.

Study design: Observational cohort study.

Setting: Patients older than 25 years old with chest pain presenting to the emergency department at a university hospital in Sweden.

Dr. Karen Clarke, assistant professor of medicine in the division of hospital medicine, Emory University, Atlanta.

Dr. Karen Clarke

Synopsis: 19,460 patients with chest pain who had at least one hs-cTn level obtained during their ED visit were included in this study. In comparison with patients who had hs-cTn less than 5 ng/L, the adjusted hazard ratios for all-cause mortality were 2.00, 2.92, 4.07, 6.77, and 9.68, in patients with hs-cTn levels of 5-9, 10-14, 15-29, 30-49, and 50 or greater ng/L, respectively. The yearly rates of MI were 0.3% and 4.5% in patients with hs-cTn levels less than 5 ng/L and 50 or greater ng/L, respectively. The yearly rates of hospitalization for heart failure were 0.1%, 1%, 2.8%, and 20% in patients with hs-cTn levels less than 5, 5-9, 10-14, and 50 or greater ng/L, respectively. There was a clear and graded association between any detectable levels of hs-cTn and risk factors for cardiovascular and noncardiovascular mortality, MI, and heart failure.

Bottom line: For patients with chest pain and stable troponin levels, there is an elevated risk of death, hospitalization for heart failure, and MI, if there is any detectable level of hs-cTn.

Citation: Roos A et al. Stable high-sensitivity cardiac troponin T levels and outcomes in patients with chest pain. J Am Coll Cardiol. 2017 Oct 31;70(18):2226-36. doi: 10.1016/j.jacc.2017.08.064.

Dr. Clarke is assistant professor of medicine in the division of hospital medicine, Emory University, Atlanta.

Recommended Reading

Post-ACS death lowered in ODYSSEY Outcomes
The Hospitalist
ODYSSEY Outcomes trial redefines secondary cardiovascular prevention
The Hospitalist
Ticagrelor noninferior to clopidogrel in terms of major bleeds in STEMI
The Hospitalist
VIDEO: Dabigatran effective for myocardial injury after noncardiac surgery
The Hospitalist
DOACs may be beneficial in post-op atrial fib after CABG
The Hospitalist
Beware of polypharmacy in patients taking warfarin
The Hospitalist
VIDEO: Andexanet alfa effectively reverses factor Xa anticoagulant
The Hospitalist
Top hospital heart failure performance translates to longer survival
The Hospitalist
Major message: Most heart failure is preventable
The Hospitalist
Warfarin dose capping avoided supratherapeutic INRs in hospitalized elderly
The Hospitalist
   Comments ()